Abstract
Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related oral mucositis. In this multicenter randomized study, we addressed whether cryotherapy during MTX administration is effective in the prevention of severe oral mucositis in patients undergoing myeloablative AHSCT. One hundred and thirty patients undergoing myeloablative AHSCT and MTX-containing GVHD prophylaxis were enrolled and randomized to receive or not receive cryotherapy during MTX administration. The incidence of severe (grade 3–4) oral mucositis, the primary end point of the study, was comparable in patients receiving or not cryotherapy. Moreover, no difference was observed in the incidence of oral mucositis grade 2–4 and the duration of oral mucositis grade 3–4 or 2–4, or in the kinetics of mucositis over time. In univariate and multivariate analysis, severe oral mucositis correlated with TBI in the conditioning regimen and lack of folinic acid rescue following MTX administration. Thus, cryotherapy during MTX administration does not reduce severe oral mucositis in patients undergoing myeloablative allogeneic HSCT. Future studies will assess cryotherapy before allogeneic HSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Scully C, Epstein J, Sonis S . Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003; 25: 1057–1070.
Scully C, Epstein J, Sonis S . Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 2004; 26: 77–84.
Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ . Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8: 33–39.
Tonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of Hematopoietic Stem-cell Transplantation. J Clin Oncol 2001; 19: 2201–2205.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al. Clinical practice guideline for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100 (S9): 2026–2046.
Mead G . Management of oral mucositis associated with cancer chemotherapy. Lancet 2002; 359: 815–816.
Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9: 449–452.
Cascinu S, Fedeli A, Fedeli SL, Catalano G . Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994; 30B: 234–236.
Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72: 2234–2238.
Lilleby K, Garcia P, Gooley T, McDonnell P, Taber R, Holmberg L et al. A prospective, randomize study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 1031–1035.
Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F . Ice pops to prevent Melphalan induced stomatitis. Lancet 1996; 347: 1691–1692.
Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B . Prevention of high dose L-Pam-induced mucositis by cryotherapy. Bone Marrow Transplant 1999; 14: 492–494.
Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of Methotrexate- and non Methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383–388.
Bonini A, Bandini G, Cirio TM, Tosi P, Rosti G, Tura S . Methotrexate and delayed engraftment in allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 729–730.
Chabner BA, Amrein PC, Druker BJ, Michaelson MD, Mitsiades CS, Goss PE et al. Antineoplastic agents. In: Brunton LL, Parker KL, Buxton IL, Blumenthal DK (eds). Goodman and Gilman's Pharmacology, 11th edition (on line), chapter 51. McGraw Hill: New York, 2006.
Robien K, Schubert M, Bruemmer B, Lloyd ME, Potter JD, Ulrich CM . Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukaemia. J Clin Oncol 2004; 22: 1268–1275.
Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA . Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397–401.
Robien K, Schubert MM, Yasui Y, P Martin P, Storb R, Potter JD et al. Folic Acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation. Bone Marrow Transplant 2006; 37: 687–692.
Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogenic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 349–354.
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematology cancer. N Engl J Med 2004; 351: 2590–2598.
Acknowledgements
We thank the Italian HSCT Nurses Group (GITMO) for sponsoring the study. We also thank the staff of the HSCT unit at the Institute of Hematology and Medical Oncology Seragnoli, who cared for the patients: Marta Stanzani, Maria Benedetta Giannini, Maddalena Giovannini, Vanessa Sabbi, Emanuela Innocenti, Caterina Guarnaccio, Lucia Bertei, Serena Orlandi, Daniele Bortolotti and Francesco Talarico.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gori, E., Arpinati, M., Bonifazi, F. et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 39, 347–352 (2007). https://doi.org/10.1038/sj.bmt.1705590
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705590
Keywords
This article is cited by
-
Protective effect of cryotherapy against oral mucositis among allogeneic hematopoietic stem cell transplant recipients using melphalan-based conditioning
Supportive Care in Cancer (2023)
-
Oral cryotherapy for management of chemotherapy‐induced oral mucositis in haematopoietic cell transplantation: a systematic review
BMC Cancer (2022)
-
Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study
Supportive Care in Cancer (2020)
-
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
Supportive Care in Cancer (2020)
-
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy
Supportive Care in Cancer (2013)